Radiomics: Why Advanced Imaging Analytics Will Drive More Personalized Drug Development

April 20, 2021 | Coverage

Radiomics and advanced imaging analytics, which involve the artificial intelligence–assisted extraction of high-dimensional data from medical images, has emerged as the other side of the personalization coin. By coupling a patient’s genetic data with his or her radiomics-derived, tumor-specific structural (or phenotypic) data, drug developers can generate therapies for that individual with increased levels of precision.

For drug developers, radiomic data gathered through the advanced analysis of medical images leads to more precise profiling of patients, tumors and therapies across multiple dimensions, enabling life sciences companies to find patterns and similarities that would be unobtainable through conventional means.